Katsunori Yokoi, Japan
Nagoya University Graduate School of Medicine NeurologyAuthor Of 1 Presentation
CLINICAL FEATURES OF AT-RISK SUBJECTS FOR LEWY BODY DISEASE
Abstract
Aims
The present study aimed i) to survey the prevalence of prodromal symptoms of Lewy body disease (LBD) in Japanese health checkup examinees, for identifying at-risk subjects, ii) to clarify clinical features and natural history of such at-risk subjects.
Methods
We conducted a survey of prodromal symptoms in healthy individuals using the following self-reported questionnaires: the Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT); Self-administered Odor Question (SAOQ); REM Sleep Behavior Disorder Screening Scale (RBDSQ); Beck Depression Inventory-Second Edition (BDI-II); Epworth Sleepiness Scale (ESS); and Physical Activity Scale for the Elderly (PASE). Subjects ≥50 years of age with ≥2 core prodromal symptoms (dysautonomia, hyposmia, and RBD), were classified as at-risk. We conducted a detailed analysis with MIBG scintigraphy and DaT SPECT for these at-risk subjects.
Results
A total of 4,953 out of 12,378 (40.0%) participants completed all the questionnaires. Among 2,726 subjects ≥50 years of age, 155 (5.7%) were classified as at-risk. These subjects also had worse scores of questionnaires about depression and daytime sleepiness. Nineteen out of 55 at-risk subjects (34.5%) had a deficit in either MIBG scintigraphy or DaT SPECT, even though they had no motor or cognitive decline.
Conclusions
Approximately 6% of the population aged 50 years or older had ≥2 prodromal symptoms, and about one-third of them had a deficit in either MIBG scintigraphy or DaT SPECT. From January 2021, we will conduct a preventive clinical trial of zonisamide for these at-risk subjects.